Proteomic analysis reveals significant alternations of cardiac small heat shock protein expression in congestive

Tomohiro Dohke1, Atsuyuki Wada, Takahiro Isono

  • 1Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu, Japan.

Journal of Cardiac Failure
|February 28, 2006
PubMed
Abstract

Insights

Congestive heart failure (CHF) involves protein changes. This study found increased heat shock proteins (HSPs) and their phosphorylation in failing dog hearts, suggesting a protective role in cardiac dysfunction.

Area of Science:

  • Cardiology
  • Proteomics
  • Molecular Biology

Background:

  • Congestive heart failure (CHF) is a complex syndrome with diverse underlying mechanisms.
  • Understanding global protein expression changes is crucial for elucidating CHF pathophysiology.

Purpose of the Study:

  • To investigate global protein expression alterations in tachycardia-induced canine CHF using a proteomic approach.
  • To identify specific proteins and post-translational modifications involved in CHF development.

Main Methods:

  • Comparative proteomic analysis using 2D electrophoresis of left ventricular samples from normal and failing canine hearts.
  • Mass spectrometry for identification of differentially expressed proteins.
  • Phosphoprotein staining and Western blotting to assess protein phosphorylation levels.

Main Results:

  • Approximately 500 cardiac protein spots were analyzed, with 20 showing differential expression in CHF.
  • Increased expression of alpha B crystallin, heat shock protein (HSP) 27, and HSP20 was identified in failing hearts.
  • Elevated phosphorylation of alpha B crystallin (Ser-59) and HSP27 (Ser-78, Ser-82) was observed in CHF.

Conclusions:

  • Proteomics offers valuable insights into the molecular mechanisms underlying CHF.
  • Phosphorylated small heat shock proteins (HSPs) may play a role in mitigating cardiac dysfunction and preserving cardiomyocyte integrity during heart failure.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...